

Supplemental Table: Patients' clinical characteristics. The present study occurred in March 2017. The most recent ketamine dosing had occurred between 3 and 10 months prior to study entry.

	Diagnoses	Prior/Current Therapy	Mood Scores at Screening
1 F/22	SAD since 6y, on-going 1 x MDE 2015, in remission	P: Sertraline, venlafaxine, propranolol, CBT. Ketamine 1mg/kg sc 8-11/2016. C: Venlafaxine	HAMA: 20 MADRS: 17 FQ: 50
2 M/29	SAD since childhood, on-going PTSD since 15y, on-going MDE since 15y, intermittent, on- going	P: Fluoxetine, sertraline, venlafaxine, CBT, other psychotherapies. Ketamine 1mg/kg sc 2-5/2016. C: Citalopram, clonidine	HAMA: 23 MADRS: 29 FQ: 48
3 M/33	SAD since 11, on-going MDE intermittent, current Bulimia, 20s, in remission	P: Fluoxetine, citalopram, multiple psychotherapies. Ketamine 1mg/kg sc 10-12/2016 C: Venlafaxine, Gestalt psychotherapy	HAMA: 17 MADRS: 32 FQ: 43
4 F/25	SAD since 16y, on-going MDE intermittent, current	P: Citalopram, escitalopram, venlafaxine, fluoxetine, sertraline, multiple psychotherapies. Ketamine 1mg/kg sc 9-12/2016. C: Quetiapine	HAMA: 31 MADRS: 40 FQ: 53
5 F/33	MDE since late teens, intermittent, current SAD since late teens, current Alcohol use disorder, in remission	P: ECT, citalopram, venlafaxine, mirtazapine, lithium, tranylcypromine, multiple psychotherapies. Ketamine 1mg/kg sc 9-12/2016. C: Quetiapine	HAMA: 15 MADRS: 40 FQ: 53
6 M/24	GAD, SAD since 10y, on-going MDE intermittent, current	P: Citalopram, paroxetine, fluoxetine, mirtazapine, prior psychotherapies. Ketamine 1mg/kg sc 5-8/2016. C: Venlafaxine, nortriptyline, topiramate	HAMA: 28 MADRS: 27 FQ: 47
7 M/25	SAD since 14y, on-going MDE intermittent, current	P: Sertraline, fluoxetine, quetiapine. Ketamine 1mg/kg sc 8-11/2016. C: Fluoxetine	HAMA: 28 MADRS: 27 FQ: 47

Legend: FQ: Fear Questionnaire; GAD: Generalized Anxiety Disorder; HAMA:

Hamilton Anxiety Scale; MADRS: Montgomery-Asberg Depression Rating Scale;

MDE: Major Depressive Episode; SAD: Social Anxiety Disorder.